TAYSHA GENE THERAPIES INC (TSHA) Stock Analyst Ratings
USA - NASDAQ:TSHA - US8776191061 - Common Stock
4.27 USD
-0.19 (-4.26%)
4.25 USD
-0.02 (-0.47%)
ChartMill assigns a Buy % Consensus number of 84% to TSHA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 9.96. This target is 133.36% above the current price.
TSHA was analyzed by 18 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about TSHA.
In the previous month the buy percentage consensus was at a similar level.
TSHA was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-21 | Raymond James | Initiate | Strong Buy |
| 2025-10-17 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-10-17 | Needham | Reiterate | Buy -> Buy |
| 2025-10-02 | Needham | Maintains | Buy -> Buy |
| 2025-10-02 | Baird | Maintains | Outperform -> Outperform |
| 2025-08-13 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-13 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-08-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-07-11 | B of A Securities | Initiate | Buy |
| 2025-07-01 | Needham | Reiterate | Buy -> Buy |
| 2025-06-10 | Needham | Reiterate | Buy -> Buy |
| 2025-06-03 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-06-02 | Needham | Reiterate | Buy -> Buy |
| 2025-05-29 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-29 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-05-16 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-04-28 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-04-28 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-04-10 | Needham | Reiterate | Buy -> Buy |
| 2025-02-27 | Needham | Reiterate | Buy -> Buy |
| 2025-02-26 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-01-06 | Needham | Reiterate | Buy -> Buy |
| 2024-11-15 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-11-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-11-14 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-11-14 | Needham | Reiterate | Buy -> Buy |
| 2024-11-12 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-11-12 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-11-12 | Needham | Reiterate | Buy -> Buy |
| 2024-08-14 | Canaccord Genuity | Maintains | Buy -> Buy |
TAYSHA GENE THERAPIES INC / TSHA FAQ
What is the average price target for TAYSHA GENE THERAPIES INC (TSHA) stock?
18 analysts have analysed TSHA and the average price target is 9.96 USD. This implies a price increase of 133.36% is expected in the next year compared to the current price of 4.27.
What is the consensus rating for TSHA stock?
The consensus rating for TAYSHA GENE THERAPIES INC (TSHA) is 84.4444 / 100 . This indicates that analysts generally have a positive outlook on the stock.